迈向重症监护实践中的公平肾功能评估:美国重症医学会肾脏临床实践多样性、公平与包容特别工作组的指导
该文由美国重症医学会肾脏临床实践多样性、公平与包容特别工作组撰写,基于文献综述与专家共识,概述了美国肾脏病学会/国家肾脏基金会(ASN/NKF)关于广泛采用新的「不含种族」肌酐方程并增加使用胱抑素C作为种族不可知GFR生物标志物的推荐。文章应用实施科学方法识别在重症监护环境中实施上述推荐促进因素与障碍:新肌酐方程成本低、较易整合入电子健康记录是促进因素;重症患者缺乏直接证据是关键障碍;胱抑素C成本较高、多数实验室缺乏检测可用性,且其浓度受炎症影响而增加解读复杂性。文章最后提出推进重症患者GFR评估的研究重点。
要点
- ASN/NKF推荐广泛采用新的「不含种族」肌酐方程,并增加使用胱抑素C作为种族不可知的GFR生物标志物。
- 实施新肌酐方程的主要障碍是重症患者缺乏直接证据;促进因素为成本低且较易整合入电子健康记录。
- 实施胱抑素C评估GFR的障碍包括成本较高、多数实验室缺乏检测可用性,且胱抑素C浓度受炎症影响而增加解读复杂性。
- 作者指出,需要开展评估重症患者GFR方程及动态肾功能评估新方法的研究,以推进这一脆弱人群的公平GFR评估。
适用人群与场景
- 危重症患者(critically ill patients)
研究设计与关键结果
- 工作组基于文献综述与专家共识,概述了ASN/NKF推荐:广泛采用新的「不含种族」肌酐方程,并增加使用胱抑素C作为种族不可知的GFR生物标志物。
- 应用实施科学方法识别促进因素:新肌酐方程成本低、较易整合入电子健康记录。
- 关键障碍为重症患者缺乏直接证据;胱抑素C相关障碍包括成本较高、多数实验室缺乏检测可用性,且其浓度受炎症影响而增加解读复杂性。
- 研究重点为推进重症患者GFR评估,包括评估GFR方程及动态肾功能评估的新方法。
证据类型、等级与局限
- 证据类型:文献综述与专家共识。
- 局限:重症患者缺乏直接证据是广泛实施新「不含种族」GFR方程的关键障碍;胱抑素C浓度受炎症影响使解读复杂化。
对床旁实践的改变
- ASN/NKF推荐广泛采用新的「不含种族」肌酐方程,并增加使用胱抑素C作为种族不可知的GFR生物标志物。
- 作者指出,重症患者缺乏直接证据是广泛实施新「不含种族」GFR方程的关键障碍;需要开展评估重症患者GFR方程及动态肾功能评估新方法的研究,以推进这一脆弱人群的公平GFR评估。
指南或共识出处
- 美国肾脏病学会/国家肾脏基金会(ASN/NKF)推荐
- 美国重症医学会肾脏临床实践多样性、公平与包容特别工作组指导文件
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Accurate glomerular filtration rate (GFR) assessment is essential in critically ill patients. GFR is often estimated using creatinine-based equations, which require surrogates for muscle mass such as age and sex. Race has also been included in GFR equations, based on the assumption that Black individuals have genetically determined higher muscle mass. However, race-based GFR estimation has been questioned with the recognition that race is a poor surrogate for genetic ancestry, and racial health disparities are driven largely by socioeconomic factors. The American Society of Nephrology and the National Kidney Foundation (ASN/NKF) recommend widespread adoption of new "race-free" creatinine equations, and increased use of cystatin C as a race-agnostic GFR biomarker.
DATA SOURCES: Literature review and expert consensus.
STUDY SELECTION: English language publications evaluating GFR assessment and racial disparities.
DATA EXTRACTION: We provide an overview of the ASN/NKF recommendations. We then apply an Implementation science methodology to identify facilitators and barriers to implementation of the ASN/NKF recommendations into critical care settings and identify evidence-based implementation strategies. Last, we highlight research priorities for advancing GFR estimation in critically ill patients.
DATA SYNTHESIS: Implementation of the new creatinine-based GFR equation is facilitated by low cost and relative ease of incorporation into electronic health records. The key barrier to implementation is a lack of direct evidence in critically ill patients. Additional barriers to implementing cystatin C-based GFR estimation include higher cost and lack of test availability in most laboratories. Further, cystatin C concentrations are influenced by inflammation, which complicates interpretation.
CONCLUSIONS: The lack of direct evidence in critically ill patients is a key barrier to broad implementation of newly developed "race-free" GFR equations. Additional research evaluating GFR equations in critically ill patients and novel approaches to dynamic kidney function estimation is required to advance equitable GFR assessment in this vulnerable population.
参考来源
- Miano TA, Barreto EF, McNett M, et al. Toward Equitable Kidney Function Estimation in Critical Care Practice: Guidance From the Society of Critical Care Medicine's Diversity, Equity, and Inclusion in Renal Clinical Practice Task Force. Crit Care Med. 2024. PMID: 38407240. doi:10.1097/CCM.0000000000006237
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。